CA2414146C - Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness - Google Patents

Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness Download PDF

Info

Publication number
CA2414146C
CA2414146C CA002414146A CA2414146A CA2414146C CA 2414146 C CA2414146 C CA 2414146C CA 002414146 A CA002414146 A CA 002414146A CA 2414146 A CA2414146 A CA 2414146A CA 2414146 C CA2414146 C CA 2414146C
Authority
CA
Canada
Prior art keywords
butyl
propyl
methyl
pentyl
iso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002414146A
Other languages
English (en)
French (fr)
Other versions
CA2414146A1 (en
Inventor
Anders Bjork
Gunnar Hedlund
Tomas Leanderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of CA2414146A1 publication Critical patent/CA2414146A1/en
Application granted granted Critical
Publication of CA2414146C publication Critical patent/CA2414146C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002414146A 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness Expired - Fee Related CA2414146C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0002531A SE0002531D0 (sv) 2000-07-05 2000-07-05 Immune Enhancement
SE0002531-2 2000-07-05
PCT/SE2001/001526 WO2002002511A1 (en) 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness

Publications (2)

Publication Number Publication Date
CA2414146A1 CA2414146A1 (en) 2002-01-10
CA2414146C true CA2414146C (en) 2008-11-25

Family

ID=20280373

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002414146A Expired - Fee Related CA2414146C (en) 2000-07-05 2001-07-03 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness

Country Status (10)

Country Link
EP (1) EP1299350B1 (https=)
JP (1) JP4864273B2 (https=)
AT (1) ATE277890T1 (https=)
AU (1) AU2001280338A1 (https=)
CA (1) CA2414146C (https=)
DE (1) DE60106036T2 (https=)
ES (1) ES2230350T3 (https=)
PT (1) PT1299350E (https=)
SE (1) SE0002531D0 (https=)
WO (1) WO2002002511A1 (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE620543A (https=) *
FR1525M (fr) * 1961-07-25 1962-11-16 Ile De France Médicaments antiémétiques nouveaux.
ES404497A1 (es) * 1972-06-20 1975-06-01 Miquel S A Lab Procedimiento para la obtencion de derivados de benzoileti-lendiaminas sustituidas.
EP0117462A3 (en) * 1983-02-28 1986-08-20 American Cyanamid Company N-(2-4-(1h-imidazol-1-yl)alkyl)arylamides
US4568685A (en) * 1984-02-29 1986-02-04 American Cyanamid Company N-[(1H-1,2,4-Triazol-1-yl)alkyl]-arylamides
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
CA2074061A1 (en) * 1991-08-26 1993-02-27 Ivo Monkovic Benzamide multidrug resistance reversing agents
WO1996040664A2 (en) * 1995-06-07 1996-12-19 Dade Chemistry Systems Inc. Preparation of immunogens and other conjugates of drugs
US6100299A (en) * 1996-03-08 2000-08-08 Oxigene, Inc. N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
JP3933244B2 (ja) * 1997-04-04 2007-06-20 株式会社資生堂 アルキレンジアミン誘導体及び抗潰瘍剤、抗菌剤
JPH1180107A (ja) * 1997-09-01 1999-03-26 Japan Tobacco Inc 骨形成促進剤及びアミド化合物
JP2001151742A (ja) * 1999-11-26 2001-06-05 Mitsui Chemicals Inc アニリド誘導体及びそれを含有する抗不整脈剤

Also Published As

Publication number Publication date
DE60106036T2 (de) 2006-03-02
EP1299350A1 (en) 2003-04-09
JP4864273B2 (ja) 2012-02-01
ATE277890T1 (de) 2004-10-15
SE0002531D0 (sv) 2000-07-05
EP1299350B1 (en) 2004-09-29
PT1299350E (pt) 2005-01-31
DE60106036D1 (de) 2004-11-04
WO2002002511A1 (en) 2002-01-10
CA2414146A1 (en) 2002-01-10
JP2004502668A (ja) 2004-01-29
AU2001280338A1 (en) 2002-01-14
ES2230350T3 (es) 2005-05-01

Similar Documents

Publication Publication Date Title
EP0316594B1 (en) Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
TWI332832B (en) Method for modulating calcium ion-release-activated calcium ion channels
CN101912382B (zh) 2-苯基丙酸衍生物及含有它们的药物组合物
US20030153507A1 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
JP2019518071A (ja) Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
CZ301631B6 (cs) Ortho- a meta-substituované bisarylové slouceniny a farmaceutické prostredky, které je obsahují
ES2401077T3 (es) Nuevos derivados 1,2-difenileteno para el tratamiento de enfermedades inmunológicas
JP5833745B2 (ja) 粘膜炎の治療に使用するための化合物
JPH07503018A (ja) ピリジル置換イミダゾール
JP2006503082A (ja) ヒストンデアセチラーゼの阻害剤
JP2001525392A (ja) アダマンタン誘導体
JP2011522843A (ja) 新規なカリウムチャンネルブロッカー及びその使用
JP2024515062A (ja) 重水素化ｄｈｏｄｈ阻害剤
US6420424B1 (en) CCR-3 receptor antagonists
EA028077B1 (ru) N-(4-гидрокси-4-метилциклогексил)-4-фенилбензолсульфонамиды и n-(4-гидрокси-4-метилциклогексил)-4-(2-пиридил)бензолсульфонамиды и их терапевтическое применение
CA2526991A1 (en) Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor
WO1998022442A2 (en) Pharmaceutical compositions comprising diaryl-cyclomethylenpyrazole compounds and their use as cyclooxygenase i (cox 1) inhibitors
WO2000053172A1 (en) Ccr-3 receptor antagonists
KR20120041070A (ko) Ｈｉｆ-1 활성을 저해하는 아릴옥시페녹시아크릴계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
EP0221511B1 (en) 2-aminosulfonyl-6-nitrobenzoic esters or amides, process for their preparation and pharmaceutical compositions containing them
CA2486872A1 (en) Nf-kb inhibitors and uses thereof
US6518312B2 (en) Immune enhancement
WO2000027800A1 (en) Ccr-3 receptor antagonists
CA2414146C (en) Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness
US7176310B1 (en) Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170704